Minimal residual disease analysis in childhood mature B‐cell leukaemia/lymphoma treated with AIEOP LNH‐97 protocol with/without anti‐CD20 administration.

Authors :: Mussolin, Lara
Lovisa, Federica
Gallingani, Ilaria
Cavallaro, Elena
Carraro, Elisa
Damanti, Carlotta C.
Vinti, Luciana
Sala, Alessandra
Micalizzi, Concetta
Santoro, Nicola
Piglione, Matilde
Cellini, Monica
Buffardi, Salvatore
Buldini, Barbara
D'Amore, Emanuele S. G.
Biffi, Alessandra
Pillon, Marta
Source :: British Journal of Haematology. May2020, Vol. 189 Issue 3, pe108-e111. 4p. 1 Chart, 1 Graph.
Publication Year :: 2020
Abstract: Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration Keywords: B-cell acute leukaemia; Burkitt; AIEOP LNH-97; anti-CD20; paediatric; minimal residual disease EN B-cell acute leukaemia Burkitt AIEOP LNH-97 anti-CD20 paediatric minimal residual disease e108 e111 4 04/30/20 20200501 NES 200501 Burkitt lymphoma (BL) and mature B-cell acute leukaemia (B-AL) are the most frequent mature B-cell neoplasms to occur in children and adolescents (Cairo I et al. i , [2]). B-cell acute leukaemia, Burkitt, AIEOP LNH-97, anti-CD20, paediatric, minimal residual disease. [Extracted from the article]

Full Text Access

Tools